Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 45%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is a company that specializes in the development and manufacture of medical devices for interventional medical specialties, with a focus on less invasive procedures. They have a diverse product portfolio and international presence, which accounts for 36% of their total sales. However, recent clinical trials have raised concerns about their WATCHMAN device and reimbursement for certain procedures may be impacting growth. Despite these challenges, Boston Scientific has gradually improved its operating margin and continues to invest in new products and M&A, leading to a positive outlook from this financial analyst.

Bears say

Boston Scientific is facing a challenging market environment, with reduced sales growth expectations in key franchises such as Farapulse and Watchman. With increased scrutiny on management credibility, the stock has declined significantly and now trades at a valuation below its peers. While the company's diverse product portfolio and potential for future growth are positives, risks remain including competition, changes in procedures, and potential regulatory challenges. A conservative estimate for the company's future performance results in a reduced price target of $65.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 45% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.